Therapy
Targeting microRNAs with small molecules: from dream to reality.
Zhang S, Chen L, Jung EJ, Calin GA.
Clin Pharmacol Ther. 2010 Jun;87(6):754-8.
Deal watch: GSK invests in targeting microRNA for the treatment of hepatitis C.
[No authors listed]
Nat Rev Drug Discov. 2010 May;9(5):350.
RNA interference: Homing in on delivery.
Baker M.
Nature. 2010 Apr 22;464(7292):1225-8.
RNA interference: MicroRNAs as biomarkers.
Baker M.
Nature. 2010 Apr 22;464(7292):1227.
Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling.
Kasinski AL, Slack FJ.
Curr Opin Mol Ther. 2010 Apr;12(2):147-57.
Targeting Toll-like receptors: emerging therapeutics?
Hennessy EJ, Parker AE, O'Neill LA.
Nat Rev Drug Discov. 2010 Apr;9(4):293-307.
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model.
Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA.
Nat Biotechnol. 2010 Apr;28(4):341-7.
Regression of murine lung tumors by the let-7 microRNA.
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ.
Oncogene. 2010 Mar 18;29(11):1580-7.
Locked nucleic acids: promising nucleic acid analogs for therapeutic applications.
Veedu RN, Wengel J.
Chem Biodivers. 2010 Mar;7(3):536-42.
Hepatitis C virus therapy: blocking the little microRNA helper of the virus.
Berkhout B.
J Formos Med Assoc. 2010 Mar;109(3):173-6.
Small molecule modifiers of the microRNA and RNA interference pathway.
Deiters A.
AAPS J. 2010 Mar;12(1):51-60.
miR-122 continues to blaze the trail for microRNA therapeutics.
Haussecker D, Kay MA.
Mol Ther. 2010 Feb;18(2):240-2.
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H.
Science. 2010 Jan 8;327(5962):198-201.
[RNA interference (RNAi) and its therapeutic potential in cancer]
Vázquez-Vega S, Contreras-Paredes A, Lizano-Soberón M, Amador-Molina A, García-Carrancá A, Sánchez-Suárez LP,
Benítez-Bribiesca L.
Rev Invest Clin. 2010 Jan-Feb;62(1):81-90.
MicroRNAs in common diseases and potential therapeutic applications.
Tsai LM, Yu D.
Clin Exp Pharmacol Physiol. 2010 Jan;37(1):102-7.
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle
genes.
Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T.
Mol Ther. 2010 Jan;18(1):181-7.
microRNA: emerging therapeutic targets in acute ischemic diseases.
Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F.
Pharmacol Ther. 2010 Jan;125(1):92-104.
Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy.
Holmstrøm K, Pedersen AW, Claesson MH, Zocca MB, Jensen SS.
Hum Immunol. 2010 Jan;71(1):67-73.
RNA therapeutics: function, design, and delivery. Preface.
Sioud M.
Methods Mol Biol. 2010;629:v-vii.
Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro.
Ren Y, Kang CS, Yuan XB, Zhou X, Xu P, Han L, Wang GX, Jia Z, Zhong Y, Yu S, Sheng J, Pu PY.
J Biomater Sci Polym Ed. 2010;21(3):303-14.
A new approach for therapeutic use by RNA interference in the brain.
Akaneya Y.
Methods Mol Biol. 2010;623:313-24.
Inhibitory RNA molecules in immunotherapy for cancer.
Mao CP, Wu TC.
Methods Mol Biol. 2010;623:325-39.
Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy.
Wu C, Lin J, Hong M, Choudhury Y, Balani P, Leung D, Dang LH, Zhao Y, Zeng J, Wang S.
Mol Ther. 2009 Dec;17(12):2058-66.
Therapeutic microRNA strategies in human cancer.
Li C, Feng Y, Coukos G, Zhang L.
AAPS J. 2009 Dec;11(4):747-57.
Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.
He S, Zhang D, Cheng F, Gong F, Guo Y.
Mol Biol Rep. 2009 Nov;36(8):2153-63.
MicroRNAs and apoptosis: implications in the molecular therapy of human disease.
Yang BF, Lu YJ, Wang ZG.
Clin Exp Pharmacol Physiol. 2009 Oct;36(10):951-60.
MicroRNAs and future therapeutic applications in cancer.
Casalini P, Iorio MV.
J BUON. 2009 Sep;14 Suppl 1:S17-22.
siRNA and miRNA for the treatment of cancer.
Jankovic R, Radulovic S, Brankovic-Magic M.
J BUON. 2009 Sep;14 Suppl 1:S43-9.
MicroRNAs and their antagonists as novel therapeutics.
Shomron N.
Eur J Cancer. 2009 Sep;45 Suppl 1:388-90.
Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded
MicroRNA-15a.
Nagata Y, Nakasa T, Mochizuki Y, Ishikawa M, Miyaki S, Shibuya H, Yamasaki K, Adachi N, Asahara H, Ochi M.
Arthritis Rheum. 2009 Sep;60(9):2677-83.
MicroManipulating viral-based therapeutics.
Tenoever B.
Discov Med. 2009 Aug;8(41):51-4.
Antisense inhibitors, ribozymes, and siRNAs.
Thompson AJ, Patel K.
Clin Liver Dis. 2009 Aug;13(3):375-90.
let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression.
Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, Escourrou J, Buscail L, Cordelier P.
Hum Gene Ther. 2009 Aug;20(8):831-44.
MicroRNA reexpression as differentiation therapy in cancer.
Mishra PJ, Merlino G.
J Clin Invest. 2009 Aug;119(8):2119-23.
Progress and challenges in RNA interference therapy for Huntington disease.
Harper SQ.
Arch Neurol. 2009 Aug;66(8):933-8.
Concepts in in vivo siRNA delivery for cancer therapy.
Gondi CS, Rao JS.
J Cell Physiol. 2009 Aug;220(2):285-91.
Lentiviral delivery of short hairpin RNAs.
Manjunath N, Wu H, Subramanya S, Shankar P.
Adv Drug Deliv Rev. 2009 Jul 25;61(9):732-45.
Small silencing RNAs: state-of-the-art.
Grimm D.
Adv Drug Deliv Rev. 2009 Jul 25;61(9):672-703.
(micro)Genomic medicine: microRNAs as therapeutics and biomarkers.
Saunders MA, Lim LP.
RNA Biol. 2009 Jul;6(3):324-8.
Micromanipulating cancer: microRNA-based therapeutics?
Petrocca F, Lieberman J.
RNA Biol. 2009 Jul;6(3):335-40.
p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication.
Gürlevik E, Woller N, Schache P, Malek NP, Wirth TC, Zender L, Manns MP, Kubicka S, Kühnel F.
Nucleic Acids Res. 2009 Jul;37(12):e84.
New hope for a microRNA therapy for liver cancer.
Rossi JJ.
Cell. 2009 Jun 12;137(6):990-2.
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.
Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR,
Mendell JR, Mendell JT.
Cell. 2009 Jun 12;137(6):1005-17.
A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis.
Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA.
Cell. 2009 Jun 12;137(6):1032-46.
A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer
cells.
Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y, Tokino T.
Clin Cancer Res. 2009 Jun 1;15(11):3725-32.
Prospects of RNAi and microRNA-based therapies for hepatitis C.
Pan Q, Tilanus HW, Janssen HL, van der Laan LJ.
Expert Opin Biol Ther. 2009 Jun;9(6):713-24.
Ellagitannin (BJA3121), an anti-proliferative natural polyphenol compound, can regulate the expression of MiRNAs in HepG2 cancer cells.
Wen XY, Wu SY, Li ZQ, Liu ZQ, Zhang JJ, Wang GF, Jiang ZH, Wu SG.
Phytother Res. 2009 Jun;23(6):778-84.
Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells.
Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, Seymour LW.
PLoS Pathog. 2009 May;5(5):e1000440.
Vascular smooth muscle-specific knockdown of the noncardiac form of the L-type calcium channel by microRNA-based short hairpin RNA
as a potential antihypertensive therapy.
Rhee SW, Stimers JR, Wang W, Pang L.
J Pharmacol Exp Ther. 2009 May;329(2):775-82.
Glioma angiogenesis: Towards novel RNA therapeutics.
Würdinger T, Tannous BA.
Cell Adh Migr. 2009 Apr;3(2):230-5.
Effect of Onconase on double-stranded RNA in vitro.
Saxena A, Saxena SK, Shogen K.
Anticancer Res. 2009 Apr;29(4):1067-71.
RNA-based therapeutics--from design to the clinic.
Iversen P.
Curr Opin Mol Ther. 2009 Apr;11(2):107.
Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency.
Keck K, Volper EM, Spengler RM, Long DD, Chan CY, Ding Y, McCaffrey AP.
Mol Ther. 2009 Mar;17(3):538-47.
The impact of microRNAs and alternative splicing in pharmacogenomics.
Passetti F, Ferreira CG, Costa FF.
Pharmacogenomics J. 2009 Feb;9(1):1-13.
MicroRNA silencing in primates: towards development of novel therapeutics.
Petri A, Lindow M, Kauppinen S.
Cancer Res. 2009 Jan 15;69(2):393-5.
Toward theragnostics.
Pene F, Courtine E, Cariou A, Mira JP.
Crit Care Med. 2009 Jan;37(1 Suppl):S50-8.
The discovery of novel experimental therapies for inflammatory arthritis.
Malemud CJ.
Mediators Inflamm. 2009;2009:698769.
RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment.
Spizzo R, Rushworth D, Guerrero M, Calin GA.
Clin Lymphoma Myeloma. 2009;9 Suppl 3:S313-8.
Silencing viral microRNA as a novel antiviral therapy?
Moens U.
J Biomed Biotechnol. 2009;2009:419539.
RNA interference technologies and therapeutics: from basic research to products.
López-Fraga M, Martínez T, Jiménez A.
BioDrugs. 2009;23(5):305-32.
MicroRNA-based therapeutics for cancer.
Wang V, Wu W.
BioDrugs. 2009;23(1):15-23.
MicroRNAs as potential cancer therapeutics.
Trang P, Weidhaas JB, Slack FJ.
Oncogene. 2008 Dec;27 Suppl 2:S52-7.
Targeting of microRNAs for therapeutics.
Stenvang J, Lindow M, Kauppinen S.
Biochem Soc Trans. 2008 Dec;36(Pt 6):1197-200.
Small noncoding RNA: novel targets for antiviral therapy.
Dölken L, Haas J.
Future Microbiol. 2008 Dec;3(6):585-8.
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs.
Aagaard LA, Zhang J, von Eije KJ, Li H, Saetrom P, Amarzguioui M, Rossi JJ.
Gene Ther. 2008 Dec;15(23):1536-49.
SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional
aberrations of nuclear import and inflammasome pathways.
Glinsky GV.
Cell Cycle. 2008 Nov 15;7(22):3564-76.
MicroRNAs as biomarkers and therapeutic drugs in human cancer.
Osaki M, Takeshita F, Ochiya T.
Biomarkers. 2008 Nov;13(7):658-70.
[Antineovascular gene therapy by Ago2 knockdown]
Hatanaka K, Shimizu K, Asai T, Oku N.
Yakugaku Zasshi. 2008 Nov;128(11):1567-75.
miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy.
Suzuki T, Sakurai F, Nakamura S, Kouyama E, Kawabata K, Kondoh M, Yagi K, Mizuguchi H.
Mol Ther. 2008 Oct;16(10):1719-26.
Effective suppression of HIV-1 by artificial bispecific miRNA targeting conserved sequences with tolerance for wobble base-pairing.
Son J, Uchil PD, Kim YB, Shankar P, Kumar P, Lee SK.
Biochem Biophys Res Commun. 2008 Sep 19;374(2):214-8.
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.
Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC.
Mol Ther. 2008 Aug;16(8):1437-43.
RNA interference: new therapeutics in allergic diseases.
Lee CC, Chiang BL.
Curr Gene Ther. 2008 Aug;8(4):236-46.
Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo.
Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P.
Mol Ther. 2008 Jun;16(6):1105-12.
Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?
Tong AW, Nemunaitis J.
Cancer Gene Ther. 2008 Jun;15(6):341-55.
MicroRNA signatures as diagnostic and therapeutic targets.
Waldman SA, Terzic A.
Clin Chem. 2008 Jun;54(6):943-4.
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM.
Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, Peschle C, Fruci D.
PLoS ONE. 2008 May 21;3(5):e2236.
Does the understanding of immune activation by RNA predict the design of safe siRNAs?
Sioud M.
Front Biosci. 2008 May 1;13:4379-92.
RNAi-based drug discovery and its application to therapeutics.
Hokaiwado N, Takeshita F, Banas A, Ochiya T.
IDrugs. 2008 Apr;11(4):274-8.
Emerging role of microRNAs in disease pathogenesis and strategies for therapeutic modulation.
Mattes J, Collison A, Foster PS.
Curr Opin Mol Ther. 2008 Apr;10(2):150-7.
Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.
Arbuthnot P, Thompson LJ.
World J Gastroenterol. 2008 Mar 21;14(11):1670-81.
MicroRNAs-based therapeutic strategy for virally induced diseases.
Sall A, Liu Z, Zhang HM, Yuan J, Lim T, Su Y, Yang D.
Curr Drug Discov Technol. 2008 Mar;5(1):49-58.
Not miR-ly small RNAs: big potential for microRNAs in therapy.
Love TM, Moffett HF, Novina CD.
J Allergy Clin Immunol. 2008 Feb;121(2):309-19.
MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management.
Lowery AJ, Miller N, McNeill RE, Kerin MJ.
Clin Cancer Res. 2008 Jan 15;14(2):360-5.
microRNAs: a new emerging class of players for disease diagnostics and gene therapy.
Zhang B, Farwell MA.
J Cell Mol Med. 2008 Jan-Feb;12(1):3-21.
Advances in microRNAs: implications for gene therapists.
Marquez RT, McCaffrey AP.
Hum Gene Ther. 2008 Jan;19(1):27-38.
Prime time for small RNA-based therapeutics.
Kay MA.
Hum Gene Ther. 2008 Jan;19(1):15-6.
RNA-Directed Therapy: The Next Step in the miRNA Revolution.
Novina CD, Chabner BA.
Oncologist. 2008 Jan;13(1):1-3.
Applying small RNA molecules to the directed treatment of human diseases: realizing the potential.
Pappas TC, Bader AG, Andruss BF, Brown D, Ford LP.
Expert Opin Ther Targets. 2008 Jan;12(1):115-27.
Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs.
Yang M, Mattes J.
Pharmacol Ther. 2008 Jan;117(1):94-104.
MicroRNAs as targets for antisense-based therapeutics.
Stenvang J, Kauppinen S.
Expert Opin Biol Ther. 2008 Jan;8(1):59-81.
Potential therapeutic applications of miRNA-based technology in hematological malignancies.
Barbarotto E, Calin GA.
Curr Pharm Des. 2008;14(21):2040-50.
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics.
McLaughlin J, Cheng D, Singer O, Lukacs RU, Radu CG, Verma IM, Witte ON.
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20501-6.
MicroRNAs in disease and potential therapeutic applications.
Soifer HS, Rossi JJ, Saetrom P.
Mol Ther. 2007 Dec;15(12):2070-9.
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C.
Pharmacol Ther. 2007 Dec;116(3):496-526.
Pharmacogenomics of microRNA: a miRSNP towards individualized therapy.
Bertino JR, Banerjee D, Mishra PJ.
Pharmacogenomics. 2007 Dec;8(12):1625-7.
AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 4.
Eccles SA.
IDrugs. 2007 Dec;10(12):844-7.
Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters.
Lo HL, Chang T, Yam P, Marcovecchio PM, Li S, Zaia JA, Yee JK.
Gene Ther. 2007 Nov;14(21):1503-12.
miRNAs and their potential for use against cancer and other diseases.
Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA.
Future Oncol. 2007 Oct;3(5):521-37.
Molecular therapy in the microRNA era.
Wurdinger T, Costa FF.
Pharmacogenomics J. 2007 Oct;7(5):297-304.
MicroRNAs as therapeutic targets in human diseases.
Jeyaseelan K, Herath WB, Armugam A.
Expert Opin Ther Targets. 2007 Aug;11(8):1119-29.
The versatility of oligonucleotides as potential therapeutics.
Eckstein F.
Expert Opin Biol Ther. 2007 Jul;7(7):1021-34.
microRNA: an emerging therapeutic.
Scaria V, Hariharan M, Brahmachari SK, Maiti S, Pillai B.
ChemMedChem. 2007 Jun;2(6):789-92.
MicroRNAs and regenerative medicine.
Yang Z, Wu J.
DNA Cell Biol. 2007 Apr;26(4):257-64.
Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions,
epigenetic changes and microRNAs.
Fojo T.
Drug Resist Updat. 2007 Feb-Apr;10(1-2):59-67.
Therapeutic potential for microRNAs.
Esau CC, Monia BP.
Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):101-14.
Locked nucleic acid oligonucleotides: the next generation of antisense agents?
Grunweller A, Hartmann RK.
BioDrugs. 2007;21(4):235-43.
Regulatory RNAs: future perspectives in diagnosis, prognosis, and individualized therapy.
Perron MP, Boissonneault V, Gobeil LA, Ouellet DL, Provost P.
Methods Mol Biol. 2007;361:311-26.
Virus-encoded microRNAs: future therapeutic targets?
Qi P, Han JX, Lu YQ, Wang C, Bu FF.
Cell Mol Immunol. 2006 Dec;3(6):411-9.
[MiRNA in disease and therapeutic development]
Tanaka Y, Kozu T.
Tanpakushitsu Kakusan Koso. 2006 Dec;51(16 Suppl):2509-14.
RNA interference: mechanisms of action and therapeutic consideration.
Rychahou PG, Jackson LN, Farrow BJ, Evers BM.
Surgery. 2006 Nov;140(5):719-25.
MicroRNA regulates the expression of human cytochrome P450 1B1.
Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T.
Cancer Res. 2006 Sep 15;66(18):9090-8.
RNA interference as potential therapy--not so fast.
Marsden PA.
N Engl J Med. 2006 Aug 31;355(9):953-4.
MicroRNAs--future drug targets?
Arenz C.
Angew Chem Int Ed Engl. 2006 Aug 4;45(31):5048-50.
Genomic approaches to drug discovery.
Ricke DO, Wang S, Cai R, Cohen D.
Curr Opin Chem Biol. 2006 Aug;10(4):303-8.
RNAi based approaches to the treatment of malignant glioma.
Mathupala SP, Guthikonda M, Sloan AE.
Technol Cancer Res Treat. 2006 Jun;5(3):261-9.
RISC control for gene therapy.
Qasim W, Thrasher AJ.
Nat Biotechnol. 2006 Jun;24(6):661-2.
Short interfering RNA (siRNA) as a novel therapeutic.
Pushparaj PN, Melendez AJ.
Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):504-10.
The role of small RNAs in human diseases: potential troublemaker and therapeutic tools.
Gong H, Liu CM, Liu DP, Liang CC.
Med Res Rev. 2005 May;25(3):361-81.
Using synthetic miRNA mimics for diverting cell fate: a possibility of miRNA-based therapeutics?
Ford LP.
Leuk Res. 2006 May;30(5):511-3.
Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer.
Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L.
Nat Med. 2006 May;12(5):585-91.
MicroRNAs as therapeutic targets.
Czech MP.
N Engl J Med. 2006 Mar 16;354(11):1194-5.
Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?
Weiler J, Hunziker J, Hall J.
Gene Ther. 2006 Mar;13(6):496-502.
Allele-specific RNA interference for neurological disease.
Rodriguez-Lebron E, Paulson HL.
Gene Ther. 2006 Mar;13(6):576-81.
MicroRNA therapeutics: a new niche for antisense nucleic acids.
Hammond SM.
Trends Mol Med. 2006 Mar;12(3):99-101.
RNA interference as potential therapy for neurodegenerative disease: applications to inclusion-body myositis?
Paulson H.
Neurology. 2006 Jan 24;66(2 Suppl 1):S114-7.
Silence of the transcripts: RNA interference in medicine.
Barik S.
J Mol Med. 2005 Oct;83(10):764-73.
RNA interference as a gene-specific approach for molecular medicine.
Grunweller A, Hartmann RK.
Curr Med Chem. 2005;12(26):3143-61.
RNA interference: a promising approach to antiviral therapy?
Silva JM, Hammond SM, Hannon GJ.
Trends Mol Med. 2002 Nov;8(11):505-8.